The hard part of buying AI agents for medical devices or AI enabled medical devices isn’t the demo. It’s proving to your quality team, your auditors, and eventually the FDA that the agent won’t compromise safety, traceability, or your clearance. Below is the evaluation framework we’d use to separate vendors who understand regulated environments from those selling a generic chatbot in a lab coat.
Quick answer: An FDA-compliant AI agent vendor is one whose product is built around a Total Product Life Cycle (TPLC) approach: documented data lineage, a Predetermined Change Control Plan (PCCP) for post-market updates, Good Machine Learning Practice (GMLP), enforced safety guardrails with human override, and immutable audit logs. Demand evidence of each before you shortlist.
What “FDA-compliant” actually means for an AI agent
There is no single “FDA-compliant” checkbox, and any vendor who claims otherwise is a red flag. Compliance is a function of your device’s intended use and risk class — not a property the agent carries on its own.
The reference point is the FDA’s January 7, 2025 draft guidance, Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations. It applies a Total Product Life Cycle lens and expects submissions to document the model, its data lineage and train/test splits, performance tied to specific clinical claims, bias analysis, the human-AI workflow, and ongoing monitoring. If the agent will update after deployment, the FDA expects a Predetermined Change Control Plan (PCCP) — a pre-authorized description of what can change, how, and within what limits — so that routine model updates don’t force a new 510(k) every time.
This matters because the distinction between an AI-enabled medical device and a true agentic system is regulatory, not marketing. An AI agent perceives, decides, and acts — it invokes tools, controls workflows, and can take action on the device. That autonomy is exactly what raises the FDA’s scrutiny, which is why your vendor’s handling of guardrails and traceability is the whole ballgame.
The seven things to verify before you shortlist a vendor
1. Regulatory-grade traceability and audit logs
Every decision the agent makes — and every input that led to it — must be reconstructable after the fact. Ask to see the actual audit trail: data, model version, prompt, policy, and action, all time-stamped and immutable. If a vendor can’t show you a single end-to-end trace during the demo, they can’t support a post-market investigation.
2. A real Predetermined Change Control Plan
Adaptive models are the reason PCCPs exist. A capable vendor will already structure their product around predefined modification categories and approval gates. Ask: “When your model updates, what changes, who approves it, and does it stay inside our cleared envelope?” A vague answer here means you inherit the regulatory risk.
3. Good Machine Learning Practice (GMLP) alignment
GMLP is the FDA/Health Canada/MHRA shared baseline for how models should be developed, validated, and maintained. Strong vendors map their development pipeline to GMLP principles explicitly and can hand your quality team the documentation rather than improvising it after you’ve signed.
4. Safety guardrails and human-in-the-loop control
For anything touching patient care, the agent needs hard limits, watchdog timers, automatic fallback to a safe mode, and a human override path that can’t be designed around. Confirm where the human sits in the loop for each use case — imaging triage tolerates a different autonomy level than infusion dosing.
5. Interoperability without re-engineering
The agent has to live inside your stack: EHR integration, device telemetry, CRM ticketing, firmware diagnostics. Ask which standards it speaks natively (HL7/FHIR, DICOM where relevant) and what integration work falls on your team versus theirs.
6. Post-market surveillance built in, not bolted on
The FDA expects heightened post-market monitoring for adaptive systems precisely because they can drift. Your vendor should provide performance monitoring, drift detection, and a defined process for surfacing and escalating anomalies — not leave you to build telemetry after launch.
7. Data lineage and bias mitigation you can defend
You will be asked how the agent performs across populations. The vendor should be able to produce data provenance, train/validation/test splits, and a documented bias analysis. If that documentation doesn’t exist, it can’t be created retroactively in a way that survives review.
Red flags that should end the conversation
A few signals reliably separate regulated-market vendors from the rest: claiming to be “FDA-approved” as a blanket status (agents aren’t approved in the abstract — devices are cleared for an intended use); no answer on PCCP or how updates stay within a cleared envelope; an audit trail they describe but can’t demonstrate; “the model just learns and improves on its own” pitched as a feature with no change control; and reluctance to share GMLP or validation documentation under NDA. Any one of these means the compliance burden quietly transfers to you.
Build vs. buy, in one line
If you’re still weighing whether to build in-house, the deciding question is rarely capability — it’s whether you want to own the PCCP, the GMLP documentation, and the post-market monitoring infrastructure yourself, or buy a vendor who already maintains them. (We cover this trade-off in depth in our build-vs-buy guide.)
A note on where the FDA is actually heading
The agency is signaling openness to more autonomous and generative systems, not less. In February 2025 it cleared Aidoc’s CARE1 foundation model for rib-fracture triage — the first FDA clearance of a foundation-model-powered clinical AI device. It later granted Breakthrough Device Designation to RecovryAI’s Virtual Care Assistants — an LLM-powered tool for joint-replacement recovery — in a move widely cited as an early signal of the FDA’s willingness to engage with patient-facing generative AI (the designation was reported in late 2025 and publicly announced by the company in early 2026). A Breakthrough designation is not a clearance, but it tells you which way the regulatory wind is blowing. Internationally, the UK’s MHRA “AI Airlock” regulatory sandbox and the EU’s CORE-MD evaluation framework point the same direction. The takeaway for vendor selection: pick a partner whose compliance posture is built for adaptive, agentic systems, because that’s the regulatory environment you’ll be operating in for the foreseeable future.
Frequently asked questions
Are AI agents considered medical devices?
An AI agent becomes a medical device when its intended use is to diagnose, treat, mitigate, or prevent disease. If it influences clinical decisions or controls a device function, the FDA generally treats it as device software (or part of one) and expects clearance for that intended use. General wellness or purely administrative agents typically fall outside that scope.
Does deploying an AI agent require a new 510(k)?
Not always. If the agent’s behavior changes within the bounds of an authorized Predetermined Change Control Plan (PCCP), routine updates can proceed without a new submission. Changes that fall outside the cleared envelope — new intended uses, new claims, or significant risk-profile shifts — generally do trigger a new 510(k) or De Novo.
What’s the difference between an AI agent and an AI-enabled medical device?
An AI-enabled device uses a model to support a function, often with a human acting on the output. An AI agent goes further: it perceives, decides, and acts — invoking tools or controlling workflows with some autonomy. That added autonomy is why agents face stricter expectations around guardrails, human oversight, and traceability.
What is a PCCP and why does it matter when choosing a vendor?
A Predetermined Change Control Plan is an FDA-recognized document that pre-authorizes specific, bounded changes to an AI model after clearance. It matters because it determines whether your vendor’s model updates can ship smoothly or force repeated regulatory submissions. A vendor without a credible PCCP transfers that burden — and risk — to you.
Is generative AI allowed in FDA-regulated medical devices?
Yes, with appropriate evidence and controls. The FDA’s recent actions — the first foundation-model clearance (Aidoc, 2025) and a Breakthrough Device Designation for a patient-facing LLM-powered recovery tool (RecovryAI) — show the pathway is open. Generative and agentic systems simply face heightened expectations for validation, guardrails, and post-market monitoring.
How many AI-enabled medical devices has the FDA authorized?
As of 2025, the FDA’s public list includes more than 1,200 AI-enabled medical devices, with the large majority authorized in the preceding three years. Radiology accounts for the bulk of authorizations. The pace has accelerated sharply — from single digits in 2015 to over 200 in 2024 alone.